GlobalData on MSN

GSK’s Blenrep gains FDA approval for myeloma treatment

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

FDA clears return of GSK’s once-withdrawn multiple myeloma drug

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...
Fierce Pharma

GSK's once-withdrawn Blenrep gets 2nd wind in US with FDA nod to treat certain myeloma patients

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...
Fierce Biotech

ESMO: GSK says 'stay tuned' for more ADC data after partner Hansoh posts 49% response rate

GSK may be happy with the latest readouts from two Hansoh-partnered antibody-drug conjugates, but the Big Pharma’s oncology R ...
BioSpace

GSK’s Blenrep Makes Comeback With FDA Nod for Third-Line Multiple Myeloma

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...
pharmaphorum

Alector ditches GSK-partnered dementia drug and cuts staff

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...
Fierce Biotech

GSK unveils positive pivotal data for Spero's once-rejected oral antibiotic

Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...